We provide evidence that endogenous myeloid AMPK signaling restricts the development of fibrosis during CDAHFD-induced NASH progression but that AMPK signaling in these cells is dispensable for metformin-associated improvements in markers of NASH. Here, PRKAA1 is linked to metabolic dysfunction-associated steatohepatitis.